NasdaqGS:BCRXBiotechs
Do BioCryst’s EAACI 2026 HAE Data Plans Subtly Recast the BCRX Long-Term Innovation Story?
BioCryst Pharmaceuticals recently announced it would present seven abstracts from its hereditary angioedema portfolio at the EAACI 2026 meeting in Istanbul, highlighting new clinical and real-world data for ORLADEYO and its investigational antibody navenibart.
This concentrated scientific presence underscores how BioCryst is working to deepen ORLADEYO’s clinical evidence base while advancing navenibart as a potential next-generation prophylactic option for hereditary angioedema.
Next, we’ll...